We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · May 23, 2022

Addition of Enzalutamide to ADT With Radiation Therapy for Patients With High-Risk Localized or Regional Nonmetastatic Prostate Cancer

Advances in Radiation Oncology


Additional Info

Advances in Radiation Oncology
Addition of Enzalutamide to Leuprolide and Definitive Radiation Therapy Is Tolerable and Effective in High-Risk Localized or Regional Nonmetastatic Prostate Cancer: Results From a Phase 2 Trial
Adv Radiat Oncol 2022 Mar 11;[EPub Ahead of Print], K Shee, CM De la Calle, AJ Chang, AC Wong, FY Feng, AR Gottschalk, PR Carroll, HG Nguyen

Further Reading